U.S. Food and Drug Administration Expands Approval of Sprycel® (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

On November 10, 2017

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219

Related Post

Dominion Energy Receives Approval from Virginia State Corporation Commission for Coastal Virginia Offshore Wind Project

11/15/2022 : Stephens Annual Investment Conference

S&P 500 High Dividend Index Methodology